Last update Aug. 30, 2021


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Synthetic progestogen structurally related to progesterone and without estrogenic or androgenic properties. It does not cause virilization (BNF 2018-2019 p478).
Indicated in the treatment of menorrgesteronehagia, endometriosis, threatening spontaneous abortion and recurrent spontaneous abortion and in cases of infertility.
Oral administration, once or twice a day.

At the date of the last update, there was no available published data on its excretion in breast milk.

Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) make it unlikely that significant amounts will be transferred to breast milk.
Other similar progestogens are excreted in negligible amounts in breast milk (HPFA 2017, Abbot 2014).

Its low oral bioavailability make it difficult for the infant to pass into plasma from ingested breast milk, except in premature infants and during the immediate neonatal period during which there may be greater intestinal permeability.


We do not have alternatives for ديدروجيستيرون.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

ديدروجيستيرون is Dydrogesterone in Arabic.

Is written in other languages:

ديدروجيستيرون is also known as


ديدروجيستيرون belongs to this group or family:


Variable Value Unit
Oral Bioavail. 28 %
Molecular weight 313 daltons
Protein Binding > 90 % %
VD 20 l/Kg
pKa 19.29 -
Tmax 0.5 - 2.5 hours
5 - 17 hours


  1. BNF. British National Formulary for Children 2018-2019 2018
  2. HPRA-Mylan. Dydrogesterone. Drug Summary. 2017 Full text (in our servers)
  3. Abbott. Dydrogesterone (Duphaston). Drug Summary. 2014 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM